VIDEO: Lower-sodium oxybate just as safe as oxybate for idiopathic hypersomnia

CHARLOTTE, N.C. – The side effect profile of lower-sodium oxybate was similar to that seen in previous sodium oxybate trials when being used to treat idiopathic hypersomnia, Richard K. Bogan, MD, FCCP, FAASM, said at SLEEP 2022.

Patients were given the FDA-approved Xywav (lower-sodium oxybate, Jazz Pharmaceuticals) 24 weeks after the primary study, and the “safety side effect profile is pretty much what we expected with oxybate,” with headache, dizziness and nausea, Bogan, medical director of SleepMed of South Carolina, said.